AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 45 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $27,000 | -74.3% | 10,900 | -28.8% | 0.00% | – |
| Q1 2022 | $105,000 | +9.4% | 15,300 | +44.3% | 0.00% | – |
| Q1 2021 | $96,000 | -45.5% | 10,600 | -59.7% | 0.00% | -100.0% |
| Q4 2020 | $176,000 | -22.8% | 26,300 | -41.9% | 0.00% | 0.0% |
| Q3 2020 | $228,000 | -27.8% | 45,300 | +15.9% | 0.00% | -50.0% |
| Q2 2020 | $316,000 | -78.7% | 39,100 | -79.1% | 0.00% | -81.8% |
| Q1 2020 | $1,486,000 | +230.2% | 187,200 | +213.8% | 0.01% | +266.7% |
| Q4 2019 | $450,000 | +248.8% | 59,654 | +91.9% | 0.00% | +200.0% |
| Q3 2019 | $129,000 | +892.3% | 31,078 | +935.9% | 0.00% | – |
| Q3 2018 | $13,000 | -96.1% | 3,000 | -90.6% | 0.00% | -100.0% |
| Q3 2017 | $336,000 | +5.3% | 32,000 | +10.7% | 0.00% | 0.0% |
| Q2 2017 | $319,000 | +398.4% | 28,900 | +337.9% | 0.00% | – |
| Q1 2017 | $64,000 | – | 6,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 1,625,000 | $12,269,000 | 3.04% |
| GENDELL JEFFREY L | 1,146,764 | $8,658,000 | 1.11% |
| Broadfin Capital, LLC | 1,029,012 | $7,769,000 | 1.04% |
| RTW INVESTMENTS, LP | 3,401,434 | $25,681,000 | 0.97% |
| BRANDES INVESTMENT PARTNERS, LP | 3,651,948 | $27,571,000 | 0.66% |
| Aristides Capital LLC | 71,520 | $540,000 | 0.42% |
| Tekla Capital Management LLC | 814,588 | $6,150,000 | 0.23% |
| INVESTORS ASSET MANAGEMENT OF GEORGIA INC /GA/ /ADV | 36,100 | $273,000 | 0.17% |
| Leap Investments LP | 43,481 | $328,000 | 0.15% |
| Brown Capital Management | 1,829,886 | $13,816,000 | 0.13% |